Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial

Avacta Therapeutics (AIM: AVCT) is heading to one of oncology’s most closely watched annual gatherings with two data presentations in tow. For investors holding AVCT through a period of clinical milestones and limited public disclosure, understanding what a conference poster actually signals, and what it does not, matters more than the headlines suggest.

The American Association for Cancer Research Annual Meeting runs from 17 to 22 April 2026 in San Diego, California. Avacta Therapeutics will present preclinical and translational data across two sessions, covering its second pipeline asset AVA6103 and a separate programme focused on dual-payload delivery within the tumour microenvironment.

What is Avacta presenting at AACR 2026 and why does it matter?

Avacta’s first poster covers AVA6103, its FAP-enabled pre|CISION peptide drug conjugate designed to deliver sustained-release exatecan directly into the tumour microenvironment. The second covers novel pre|CISION compounds engineered to deliver two complementary payloads simultaneously following FAP cleavage, an extension of the platform’s core logic that has not previously been presented in a public scientific setting.

For investors, the significance is layered. These are not clinical trial readouts. They are preclinical and translational datasets, meaning the data comes from laboratory and early mechanistic work rather than from patients enrolled in a trial. That distinction is important, and investors who conflate conference posters with Phase 1 efficacy readouts often misprice the news in both directions.

What the presentations do signal is scientific momentum. Getting two posters accepted at AACR, a meeting that draws the world’s leading oncology researchers, reflects peer-reviewed credibility for the pre|CISION platform at a stage when most investor attention is focused solely on the AVA6000 clinical timeline.

What is the pre|CISION platform and why is FAP the key mechanism to understand?

The pre|CISION platform works by attaching a highly potent cancer-killing payload to a peptide that is specifically cleaved by fibroblast activation protein, or FAP. FAP is a protease that is overexpressed in the tumour microenvironment across the vast majority of solid tumour types but is largely absent in healthy tissue.

The result is a delivery system designed to concentrate toxic payloads inside tumours while limiting exposure to surrounding normal cells. This is the core problem that has historically constrained how aggressively oncologists can dose patients with the most potent chemotherapy agents.

For investors holding Avacta Therapeutics (AIM: AVCT) shares, the clearest way to think about pre|CISION is as a targeting system. The payload, whether faridoxorubicin in AVA6000 or exatecan in AVA6103, is the warhead. The pre|CISION peptide is the address label. FAP is the lock that opens only inside tumour tissue.

The AACR 2026 presentations extend this logic in two directions: one refining AVA6103’s delivery of exatecan, and one exploring whether two different warheads can be delivered simultaneously through the same FAP-triggered mechanism.

What does the AVA6103 poster tell investors that the Phase 1 trial update did not?

AVA6103 entered its first clinical sites in March 2026, with centres at Virginia Cancer Specialists Research Institute in Fairfax and NEXT Oncology Specialists in Dallas opening for patient recruitment. The Phase 1a dose escalation study is running parallel arms across two dosing schedules, with preliminary safety and pharmacokinetic data expected in the second half of 2026.

The AACR poster sits upstream of that clinical data. It covers the preclinical characterisation of AVA6103, specifically how the compound delivers sustained-release exatecan in the tumour microenvironment and the antitumour activity observed in laboratory models.

For AVCT investors, this matters because preclinical data at a major conference gives scientific context for what the Phase 1a results will eventually be measured against. If the preclinical activity is strong and the mechanism is credible, the subsequent clinical data has a framework. If the clinical pharmacokinetic data diverges sharply from the preclinical model, that gap becomes the right question to ask on the next RNS.

What the AACR poster will not tell investors is whether AVA6103 works in patients. That requires the H2 2026 safety and pharmacokinetics readout from the Phase 1a trial. Investors should treat the conference presentation as scientific validation of the mechanism, not as a forward indicator of clinical outcome.

What is the dual payload programme and why is it the more speculative of the two presentations?

The second AACR presentation covers novel pre|CISION compounds designed to deliver complementary dual payloads to the tumour microenvironment following FAP cleavage. This programme sits earlier in development than either AVA6000 or AVA6103 and has not yet entered clinical studies.

The strategic logic is straightforward. If FAP-triggered release can deliver one payload into a tumour, the next question is whether two payloads with complementary mechanisms of action can be delivered through the same system. Combining a topoisomerase inhibitor with an immune modulator or a DNA damaging agent in a single FAP-triggered construct would represent a meaningful step forward in the platform’s commercial reach.

For investors in Avacta Therapeutics (AIM: AVCT), this presentation is worth noting but not over-weighting. Dual payload technology is compelling at the platform level and signals that the scientific team is extending pre|CISION’s architecture rather than standing still. However, the distance between a preclinical dual payload poster and a clinical programme is significant. The more immediate value drivers for AVCT remain the AVA6000 Phase 1b readout expected in H1 2026 and the AVA6103 Phase 1a safety data in H2 2026.

How should investors read a conference poster versus a clinical trial readout?

This is the most practical question for AVCT holders watching the AACR 2026 news flow.

A conference poster is a curated presentation of data selected by the company and accepted for presentation by the conference’s scientific programme committee. Acceptance signals that the work meets a threshold of scientific credibility. It does not signal that the drug works in patients, that the trial will succeed, or that a partnering conversation has begun.

A clinical trial readout, whether a safety update, a pharmacokinetics report, or an efficacy signal from a dose escalation study, involves real patient data collected under regulated trial conditions. This is the data that moves biotechs in a sustained way.

For AVCT, the AACR presentations land at a useful moment. AVA6103 has just opened its first clinical sites and the dual payload programme is emerging publicly for the first time. Conference visibility raises awareness among oncology researchers and potential partners. It can attract institutional attention that was not previously focused on the company.

What it does not do is move the clinical timeline or change the data readout schedule. Investors who buy AVCT ahead of the AACR presentations expecting a price catalyst should be clear about what they are buying into. The real catalysts remain the H1 2026 AVA6000 data and the H2 2026 AVA6103 pharmacokinetic update.

What are the key milestones AVCT investors should be tracking through the rest of 2026?

The AACR conference sits at the start of a dense milestone calendar for Avacta Therapeutics (AIM: AVCT). Investors holding through 2026 should have the following markers on their radar.

The AVA6000 Phase 1b readout is the nearest material catalyst. Avacta presented a 91% disease control rate in treated patients at the European Society for Medical Oncology meeting in late 2025, and a follow-on data update from the Phase 1b cohort is expected in the first half of 2026. This readout carries the most weight for near-term sentiment because it involves actual patient outcomes and because AVA6000 is the programme furthest along in the clinic.

The AVA6103 Phase 1a safety and pharmacokinetics data is the second major marker, expected in H2 2026. With two clinical sites now open and the first patient anticipated before the end of March 2026, the timeline is live. Investors should watch for any RNS updates on enrolment pace, which in small Phase 1 oncology trials can slip without a formal announcement.

Cash runway is the third variable. The October 2025 fundraise extended Avacta’s position into the second half of 2026, and the convertible bond restructure deferred repayments to October 2027. That provides breathing room through both near-term readouts without requiring an emergency raise, though investors should monitor the at-the-market facility usage in each RNS.

Any partnering or licensing news would represent an upside catalyst not currently priced into consensus. The AACR presentations, alongside the ESMO data already in the public domain, increase the scientific visibility of the platform to exactly the audience that initiates such conversations.

What are the key things AVCT investors should take away from the AACR 2026 presentations?

• Avacta Therapeutics (AIM: AVCT) will deliver two posters at AACR 2026 in San Diego from 17 to 22 April, covering AVA6103 preclinical data and a novel dual-payload pre|CISION programme.
• Both presentations are preclinical and translational, not clinical trial readouts, and should not be read as efficacy signals from patient data.
• The AVA6103 poster provides the first public scientific presentation of the compound’s sustained-release exatecan mechanism ahead of Phase 1a patient data expected in H2 2026.
• The dual payload presentation is the earliest-stage disclosure Avacta has made publicly and signals platform expansion beyond the current two clinical assets.
• AACR acceptance reflects peer-reviewed scientific credibility for the pre|CISION platform at a stage when most investor attention is still focused on AVA6000.
• The primary near-term catalyst for AVCT remains the AVA6000 Phase 1b readout in H1 2026, which involves actual patient outcome data.
• Investors should treat the AACR conference as a visibility and credibility event, not a clinical data catalyst.
• The AVA6103 Phase 1a trial opened its first two US centres in March 2026, with first patient enrolment anticipated before end of March.
• Cash runway extends into H2 2026 following the October 2025 raise and convertible bond deferral to October 2027, covering both major 2026 readouts without an immediate funding requirement.
• For AVCT holders, 2026 is a two-readout year with the science now publicly validated at the highest oncology conference in the world.